A new report from calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.
The report, “Making Medicines Affordable: A National Imperative,” recommends that steps be taken to address market failures that are “currently permeating” the biopharmaceutical sector: a lack of competition due to distortions in the application of patent protections; the imbalance between the negotiating power of suppliers and purchasers; and the convoluted structure of the supply chain. The report seeks methods to improve the affordability of prescription drugs without discouraging the development of new and more effective drugs for the future.
Among the report’s recommendations are the following:
The report was written by a panel of physicians, attorneys, economists, and former corporate leaders and insurance and pharmaceutical company executives who worked together to produce the independent, objective analysis. Two members of the panel filed dissenting views, as did pharma industry group Pharmaceutical Research and Manufacturers of America (PhRMA), which called the report a rehash of outdated ideas that would severely restrict patient access to innovative treatment.
The report acknowledges the biopharmaceutical sector’s success over the past several decades in developing and delivering effective drugs for improving health, combatting disease, and helping to make many health conditions previously thought to be untreatable now manageable or cured. But it decried the high and increasing costs of prescription drugs, coupled with broader trends in overall healthcare expenditures as unsustainable to society as a whole. “There is a critical need for policy changes that will ensure the availability and affordability of medicines for patients who need them,” the report notes. “There is little value in new drugs that patients cannot afford—and there is no value in drugs that do not exist. Thus, there is a fundamental tension between ensuring the availability of new drugs in the future and ensuring the affordability of those drugs that exist today.”
The report details the factors that increase the cost of drugs for patients, including:
The report also said that patients’ share of drug costs should be calculated as a fraction of the net purchase price of drugs, after rebates and discounts, rather than from list prices, to help reduce the financial burden on patients who need costly pharmaceuticals. In addition, the Justice Department and FTC should discourage direct-to-consumer advertising of prescription drugs, said the report, and discourage direct financial incentives for patients. The agencies should make sure that tax credits and incentives for development of drugs for rare diseases not be extended to widely sold drugs, and should further restrict drug company sales representatives from visiting physicians and providing free samples and other inducements.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.